In line with this hypothesis, treatment with CCX771, a CXCR7 functional antagonist, which is known to increase plasma CXCL12 levels (Berahovich et al., 2014), led to reduced alveolar inflammation and lung microvascular permeability in a murine model of ALI (Konrad et al., 2017; Ngamsri et al., 2017). This evidence concerns the gene ACKR3 and acute respiratory distress syndrome.